Variants of FasL and ABCC5 are predictive of outcome after chemotherapy-based treatment in osteosarcoma

The association of variants of FASL and ABCC5 with survival outcome after chemotherapy was validated in patients with osteosarcoma. Our findings may provide a new insight into a more personalized treatment for patients with osteosarcoma.